Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Volitionrx (VNRX) Research & Development (2019 - 2025)

Volitionrx filings provide 9 years of Research & Development readings, the most recent being $2.5 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 4.61% to $2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.1 million, a 30.02% decrease, with the full-year FY2025 number at $10.1 million, down 30.02% from a year prior.
  • Research & Development hit $2.5 million in Q4 2025 for Volitionrx, up from $2.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.5 million in Q2 2023 to a low of $2.3 million in Q3 2025.
  • Median Research & Development over the past 5 years was $3.6 million (2021), compared with a mean of $3.6 million.
  • Biggest five-year swings in Research & Development: surged 66.23% in 2023 and later crashed 43.68% in 2025.
  • Volitionrx's Research & Development stood at $3.3 million in 2021, then grew by 25.18% to $4.1 million in 2022, then increased by 10.02% to $4.5 million in 2023, then crashed by 43.06% to $2.6 million in 2024, then decreased by 4.61% to $2.5 million in 2025.
  • The last three reported values for Research & Development were $2.5 million (Q4 2025), $2.3 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.